Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2010
06/15/2010US7737261 Avermectin B1 and avermectin B1 monosaccharide derivatives having an alkoxymethyl substituent in the 4″ -or 4′-position
06/15/2010US7737214 cross-linking polysaccharide derivative containing at least one active ester group introduced in a polysaccharide side chain, which is capable of reacting with an active hydrogen-containing group; avoid risks as caused by using a non-biologically derived material
06/15/2010US7737186 mixture of 2-amino-1,3,4-octadecanetriol and lipolytic agents, which stimulates the synthesis of leptin by adipocytes, for reducing subcutaneous fats
06/15/2010US7737185 treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels
06/15/2010US7737184 2-(3-Phenyl-ureido)-octanedioic acid 8-hydroxyamide 1-phenylamide; 4-(2-Hydroxycarbamoyl-vinyl)-N,N-bis-phenylcarbamoylmethyl-benzamide; useful in treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, and neurdegenerative disorders
06/15/2010US7737183 β-amyloid and neurofibrillary tangle imaging agents
06/15/2010US7737182 Applying a prostaglandin D receptor selective agonist, e.g., a 1R,2R,3R,5R)-5-halo-2-[(1E,3S)-3-cycloalkyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-(5Z)-5-alkenoic acid; in particular treating senile xeroderma.
06/15/2010US7737181 Topical adapalene for acne and other inflammatory or proliferative skin disorders
06/15/2010US7737180 treating schizophrenia in a patient by administering an effective amount of 4,4-dimethylcyclohexylamine
06/15/2010US7737179 Methods for treatment of dermatological conditions
06/15/2010US7737178 Administering a combination of an omega-3 fatty acid and aspirin, to a patient suffering from inflammation, arthritis or cardiovascular diseases; reduced side effects; 13-hydroxy-DHA (13-hydroxy-DHA)
06/15/2010US7737177 Combining solution of pseudomonic acid in water-immiscible solvent with suspension or solution of calcium C2-C12 organic carboxylate in aqueous solvent to form aqueous and nonaqueous phases, wherein mupirocin calcium dihydrate precipitates
06/15/2010US7737176 Substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositions comprising them and processes for the preparation of them
06/15/2010US7737175 administering a histone deacetylase enzyme inhibitor for increasing muscle fiber formation in body; decreasing inflammatory cytokine activity in a cell
06/15/2010US7737174 6-Chloro-N-3,4-dihydroxybutyl)-5-fluoro-4'-(4-fluorophenyl)-2'-neopentyl-2-oxyspiro[indoline-3,3'-pyrrolidine]-5'-carboxamide; antagonists of the interaction p53 and MDM2 proteins; anticarcinogenic, -proliferative agents; side effect protection of cancer therapy; sensitizers to apoptosis inducers
06/15/2010US7737173 1-Benzyl-5-hydroxy-2-methyl-1H-indole-3-carboxylic Acid, 3,5-Difluorobenzylamide, useful for treating vision defects, angiogenesis, cardiovascular disorders and as wound healing agents
06/15/2010US7737172 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one, used for treating cellular proliferative disorders, nonproliferative degenerative disorders and viral diseases or infections
06/15/2010US7737171 Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
06/15/2010US7737170 Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS
06/15/2010US7737169 as caged compounds from which effector species such as neurotransmitters and amino acids are releasable on irradiation with light
06/15/2010US7737168 Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
06/15/2010US7737167 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
06/15/2010US7737166 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides
06/15/2010US7737165 Methods of reducing weight gain associated with olanzapine treatment
06/15/2010US7737164 Cyanopyridine antibacterial agents
06/15/2010US7737163 Benzimidazolone carboxylic acid derivatives
06/15/2010US7737162 Viral inhibitors
06/15/2010US7737161 such as 5-amino-N-(5-chloropyridin-2-yl)-3-{[(trans-4-pyrrolidin-1-ylcyclohexyl)carbonyl]amino}furo[3,2-b]pyridine-2-carboxamide, used as activated blood coagulation factor X inhibitors
06/15/2010US7737160 Protein tyrosine kinase inhibitors such as N-[4-(4-aminothieno[3,2-]pyridin-3-yl)-2-fluorophenyl]-N'-(3'-methylphenyl)urea, used for treating lung, breast, colon or hematopoietic cancer
06/15/2010US7737159 such as 2-(3-(aminomethyl)pyrrolidin-1-yl)-4-(4-methoxybenzyl)-7-oxo-4,7-dihydro[1,3]thiazolo[4,5-b]pyridine-6-carboxylic acid, used for treating drug-resistant bacterial infections
06/15/2010US7737158 Processes for regulating blood glucose in a mammal
06/15/2010US7737157 such as 6-((2-(3-(dimethylamino)phenylamino)pyrimidin-4-yl)(methyl)amino)-N,2-dimethylbenzofuran-3-carboxamide, used for treating angiogenesis-related disorders selected from rheumatoid arthritis, age-related macular degeneration and psoriasis; inhibitors of kinase insert domain receptor (KDR)
06/15/2010US7737156 6-(Cyclohexylmethyl)-1-(1-ethylpropyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, administered to humans or animals, to improve perception, concentration, cognition, learning and/or memory, as a consequence of dementia, stroke, brain trauma, Alzheimer's disease, Parkinson's disease or depression
06/15/2010US7737155 nicotinic receptor agonist useful for treating metabolic syndrome, dyslipidemia, cardiovascular diseases, disorders of the peripheral and central nervous system, hematological diseases, cancer, inflammation, respiratory diseases, gastrointestinal diseases, diabetes, and non-alcoholic fatty liver diseases
06/15/2010US7737154 CRF receptor antagonists and methods relating thereto
06/15/2010US7737153 Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
06/15/2010US7737152 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds
06/15/2010US7737151 such as N-(4-(6-(5-methylthiazol-2ylamino)pyrazin-2-ylthio)phenyl)cyclopropanecarboxamide, used treating or preventing autoimmune, inflammatory and neurodegenerative diseases, bone, metabolic, nervous system and cardiovascular disorders, cancer, allergies, asthma and Alzheimer's disease
06/15/2010US7737150 N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer
06/15/2010US7737149 Heterocyclic amides as anticancer agents
06/15/2010US7737148 Hydroxyiminopiperazines administered to animals as analgesics; inhibitors of vanilloid receptors
06/15/2010US7737147 Administering l-deprenyl or propargylamine compounds; treating male and female sexual disorders, brain disorders, vascular disorders, anorectal disorders, stroke or inflammatory disorders, and depression
06/15/2010US7737146 Compound, useful for pancreatic lipase inhibition and the process for isolation thereof
06/15/2010US7737145 Diamine derivatives as inhibitors of leukotriene A4 hydrolase
06/15/2010US7737144 1-Ethyl-6-methyl-3-phenyl-1H-pyrinido[5,4-e]1,2,4]triazine-5,7-dione, used for lowering blood sugar, treating non-insulin dependent diabetes and insulin resistance; antidiabetic agents
06/15/2010US7737143 such as 6-(1H-Benzimidazol-1-yl)-N-benzylpyrazin-2-amine, used as antidiabetic, anticarcinogenic and antiarthritic agents or for treating autoimmune diseases
06/15/2010US7737142 (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
06/15/2010US7737141 Prodrug of cinnamide compound
06/15/2010US7737140 Therapeutic compounds
06/15/2010US7737139 useful in inhibiting the chernotactic activation of neutrophils, induced by the interaction of Interleukin-8 (IL-8) with chemokine membrane receptors
06/15/2010US7737138 Methods of treatment of a tauopathy condition comprising the use of thioninium compounds
06/15/2010US7737137 Treating non-insulin dependent diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome; 6-[(1-cycloheptyl-4,4-dimethyl-5-oxopyrrolidin-3-yl)methoxy]nicotinonitrile for example
06/15/2010US7737136 high affinity agonists; high specificity; side effect reduction; endometriosis; hormone dependent cancers, fertility control; dibenzo[b,f]pyrido[1,2-d][1,4] oxazepin, dibenzo[b,f]pyrido[1,2-d][1,4]thiazepim, dibenzo[b,f]pyrido[1,2-d][1,4]diazepin and dibenzo[c,f]pyrido[1,2-a]azepine derivatives
06/15/2010US7737135 (2S)-2-[[4'-(methylsulfonyl)-3',5-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]oxy]-propanoic acid for example; asthma or rhinitis; orphan receptor CRTH2 modulators, prostaglandin D2 is a ligand of CRTH2
06/15/2010US7737134 pateamine A analogs, having antiproliferative effects in vivo and in vitro by a novel drug mechanism of action, including inhibition of eukaryotic initiation factor-4A (eIF4A)-dependent translation initiation, causing cell cycle arrest or inducing apoptosis in transformed cells; treatment of leukemia
06/15/2010US7737133 Formulations and methods of treating inflammatory bowel disease
06/15/2010US7737132 potentiating activity of an antibiotic to inhibit growth of a bacterium which is resistant to said antibiotic, by contacting the bacterium with said antibiotic and a new class of antibiotics which are derivatives of beta-cyclodextrin, which is a cyclic molecule comprising seven D-glucose units
06/15/2010US7737131 Multifunctional and biologically active matrices from multicomponent polymeric solutions
06/15/2010US7737130 Pharmaceutical compositions for topical use in treatment of skin or mucous injuries
06/15/2010US7737129 Treating sepsis, septicemia and septic shock
06/15/2010US7737128 treating an individual exhibiting one or more symptoms of bipolar disorder by administering to the individual a therapeutically-effective amount of a uridine composition that provides 1 to 7 grams of uridine per day
06/15/2010US7737127 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
06/15/2010US7737126 agonist of adenosine A2A receptor; treatment of asthma and chronic obstructive pulmonary disease; example: (2R,3R,4S,5R,2'R,3'R,4'S,5'R)-2,2'-{trans-1,4-cyclohexanediylbis[imino(2-{[2-(1-methyl-1H-imidazol-4-yl)ethyl]amino}-9H-purine-6,9-diyl)]}bis[5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol]
06/15/2010US7737124 transfecting a packaging cell line with a retroviral construct, then recovering a recombinant retrovirus from the packaging cell line and infecting a target cell ex vivo with the recombinant retrovirus; downregulating chemokine receptors (CCR5); treatment of viral diseases
06/15/2010US7737123 Multidrug resistant anticancer anthracyclines
06/15/2010US7737122 controlling arthropod pests such as beetles, cockroaches, or ants by dispersing spinosyn compositions in the form of aerosols, fogs, smokes, or vapors
06/15/2010US7737121 Insulin secretion by anthocyanins and anthocyanidins
06/15/2010US7737118 Alternating intrathecal administration to the mammal of a pharmaceutically effective dose of opioid receptor agonist for first period of time, and dose of at least one opioid receptor-like receptor 1 agonist for a second period of time
06/15/2010US7737108 Enhanced transport using membrane disruptive agents
06/15/2010US7736885 Method for production of arachidonic acid
06/15/2010US7736873 An isolated nucleic acid molecule comprising a nucleotide sequence which encodes the polypeptide comprising the outer membrane protein antigens of gramnegative bacteria, which can be used to prevent and treat gramnegative bacteria infection in mammals, such as humans; immunology; vaccines
06/15/2010US7736856 determining whether catechin or an antibody has the same pharmacological effect as that of epigallocatechin gallate, on inhibiting cell proliferation, angiogenesis or cancer cell metastasis, as a neuroprotectant, a viricide, an antiallergen and as a antiarteriosclerotic agent
06/15/2010US7736679 comprises curcumin and an essential oil of turmeric
06/15/2010US7736678 Method of enhancing blood antioxidant activity ingesting a compound in the form of at least one form selected from amongst juice, powder, granule, tablet and capsule, which contains an effective amount of at least one vegetable selected from the group consisting of broccoli, spinach, parsley, komatsuna (Brassicad rapa L.) and japanese radish leaves, and at least one vegetable selected from amongst lettuce, cabbage and celery
06/15/2010US7736675 Aqueous extract of stems or leaves or stems and leaves of one or more Cissus quandragularis plants to promote weight loss; combined with chitosan and/or a chitosan derivative and an antioxidant such as vitamin C and vitamin E
06/15/2010US7736673 Stabilized pharmaceutical product
06/15/2010US7736670 The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the
06/15/2010US7736668 A delayed delivery drug dose to a fluid environment consists of a dose of drug, a second formulation with imbibes fluid and expands, a wall that confines both and permeable to the passage of fluid, a subcoat of hydroxyalkyl cellulose
06/15/2010US7736667 Release rate constant over time for several hours within the early part of the release profile, confining the release to the upper GI tract; shell remains intact during entire period of drug release
06/15/2010US7736666 Consists of naproxen, a butyl spacer and a nitrogen oxide (NO)-releasing nitrate group, linked together into a single molecule; useful as antiinflammatory agent and an analgesic
06/15/2010US7736665 Implantable polymeric device for sustained release of buprenorphine
06/15/2010US7736654 Proteins, polynucleotides, antibodies, transgenic animals, hybridoma; humoral or cellular immune response; pancreatic
06/15/2010US7736636 Mixture of nicotine polymer and vasodilator; promote angiogenesis; therapy for erectile dysfunction, cardiovascular disorders, strokes
06/15/2010US7736635 3-Maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide linked to 2 polyoxyethyelne glycol residue and two antibodies or fragments; conjugate; biodegradable
06/15/2010US7736634 Acryloyloxy-capped siloxane oligomer; copolymers with unsaturated monomers; antifouling coatings for underwater structures
06/15/2010US7736628 Mixing a lactose fraction with small particle size with a carrier lactose contains amorphous lactose, exposing lactose mixture to a relative humidity of 85 % at a temp. from 20-40 degree C., then relative humidity of less than 20% at a temp.70 degree C. so that a modified lactose mixture is produced
06/15/2010US7736627 The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1 7-((hydroxydi-2-thienylacetyl)oxy)-9, 9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane-bromide, with a simple monoclinic cell, and one or more adjuvants
06/15/2010US7736626 HFA supension formulations containing an anticholinergic
06/15/2010US7736624 derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy
06/15/2010US7736622 Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
06/15/2010CA2686480A1 New salts
06/15/2010CA2599888C Preparation of taxanes from 9-dihydro-13-acetylbaccatin iii
06/15/2010CA2564369C Delta crystalline form of ivabradine chlorhydrate, process for its preparation and pharmaceutical compositions containing it
06/15/2010CA2555800C Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
06/15/2010CA2538915C [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
06/15/2010CA2529686C 2-acylaminothiazole derivative or salt thereof
06/15/2010CA2521647C Novel hydroxamates as therapeutic agents
06/15/2010CA2518224C Novel isothiazolopyrimidinones and isoxazolopyrimidinones and uses thereof
06/15/2010CA2499691C Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
06/15/2010CA2495577C Novel benzoimidazole derivatives useful as antiproliferative agents